Advertisement

Drugs

, Volume 76, Issue 16, pp 1567–1578 | Cite as

Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C

  • Sarah L. Greig
Adis Drug Evaluation

Abstract

A once-daily, single-tablet, pangenotypic regimen comprising the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir and the HCV NS5A inhibitor velpatasvir (sofosbuvir/velpatasvir; Epclusa®) was recently approved for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in the USA, EU and Canada. In the phase III ASTRAL trials, once-daily oral sofosbuvir/velpatasvir for 12 weeks provided very high rates of sustained virological response at 12 weeks post treatment (SVR12) in treatment-naive and -experienced patients with chronic HCV genotype 1–6 infection, including those with compensated cirrhosis or HIV-1 co-infection. High SVR12 rates were also observed with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with chronic HCV genotype 1–6 infection and decompensated cirrhosis. Sofosbuvir/velpatasvir was generally well tolerated, with low rates of adverse events. Thus, sofosbuvir/velpatasvir represents a valuable treatment option in adults with chronic HCV genotype 1–6 infection, including those with compensated or decompensated cirrhosis, previous treatment experience or HIV-1 co-infection.

Keywords

Sustained Virological Response Sofosbuvir Decompensated Cirrhosis SVR12 Rate NS5A RAVs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

During the peer review process, the manufacturer of sofosbuvir/velpatasvir was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Sarah Greig is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57.CrossRefPubMedGoogle Scholar
  2. 2.
    American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2016. http://www.hcvguidelines.org. Accessed 23 Sep 2016.
  3. 3.
    European Association for the Study of the Liver. EASL recommendations of treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.CrossRefGoogle Scholar
  4. 4.
    Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43(12):1276–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang J, Nguyen D, Hu KQ. Chronic hepatitis C virus infection: a review of current direct-acting antiviral treatment strategies. N Am J Med Sci. 2016;9(2):47–54.Google Scholar
  6. 6.
    Gilead Sciences Inc. Epclusa® (sofosbuvir and velpatasvir) tablets, for oral use: US prescribing information. 2016. http://www.fda.gov. Accessed 23 Sep 2016.
  7. 7.
    Gilead Sciences International Ltd. Epclusa® 400/100 mg film-coated tablets: EU summary of product characteristics. 2016. http://www.ema.europa.eu. Accessed 23 Sep 2016.
  8. 8.
    Gilead Sciences Canada. Epclusa™ (sofosbuvir/velpatasvir) tablets 400 mg/100 mg antiviral agent: Canadian product monograph. 2016. http://www.gilead.ca. Accessed 23 Sep 2016.
  9. 9.
    Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs. 2014;74(10):1127–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Mariño Z, van Bömmel F, Forns X, et al. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut. 2014;63(2):207–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54(7):677–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.CrossRefPubMedGoogle Scholar
  13. 13.
    Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17.CrossRefPubMedGoogle Scholar
  14. 14.
    Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28.CrossRefPubMedGoogle Scholar
  15. 15.
    Bräu N, Wyles D, Kottilil S, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study [abstract no. WEAB0301 plus slides]. In: International AIDS Conference. 2016.Google Scholar
  16. 16.
    Hezode C, Reau N, Svarovskaia E, et al. Resistance analysis in 1284 patients with genotype 1 to 6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4 studies [abstract no. THU-216 plus poster]. J Hepatol. 2016;64(Suppl 2):S399–400.CrossRefGoogle Scholar
  17. 17.
    Lawitz EJ, Dvory-Sobol H, Doehle BP, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother. 2016;60(9):5368–78.CrossRefPubMedGoogle Scholar
  18. 18.
    Mogalian E, Brainard D, Denning J, et al. Evaluation of the effect of GS-5816, a pangenotypic HCV NS5A inhibitor, on the QT/QTc interval in healthy subjects [abstract no. 45 plus poster]. Rev Antivir Ther Infect Dis. 2015;4:49–50.Google Scholar
  19. 19.
    Mogalian E, Osinusi A, Shen G, et al. Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of sofosbuvir/velpatasvir fixed-dose combination tablet [abstract no. PI-050 plus poster]. Clin Pharmacol Ther. 2016;99(Suppl 1):S43–4.Google Scholar
  20. 20.
    Mogalian E, Mathias A, Brainard D, et al. The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment [abstract no. P0712 plus poster]. J Hepatol. 2015;62(Suppl 2):S590–1.CrossRefGoogle Scholar
  21. 21.
    Mogalian E, Brainard D, McNally J, et al. Lack of clinically relevant pharmacokinetic drug-drug interaction between norgestimate/ethinyl estradiol and pangenotypic HCV NS5A inhibitor GS-5816 in HCV-uninfected female subjects [abstract no. 1998 plus poster]. Hepatology. 2014;60(4 Suppl):1173A.Google Scholar
  22. 22.
    Mogalian E, McNally J, Shen G, et al. Drug-drug interaction profile of sofosbuvir/velpatasvir fixed-dose combination [abstract no. FRI-168]. J Hepatol. 2016;64(2 Suppl 1):S613–4.Google Scholar
  23. 23.
    Mogalian E, Naik S, Natha M, et al. Drug-drug interaction studies between HCV antivirals sofosbuvir and velpatasvir and HIV antiretrovirals [abstract no. P6]. HIV Med. 2016;17(Suppl 1):16.Google Scholar
  24. 24.
    Mogalian E, Stamm LM, Osinusi A, et al. Drug interaction studies between sofosbuvir/velpatasvir and boosted HIV ARV regimens [abstract no. 100 plus slides]. In: Conference on Retroviruses and Opportunistic Infections. 2016.Google Scholar
  25. 25.
    Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):818–26.CrossRefPubMedGoogle Scholar
  26. 26.
    Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):809–17.CrossRefPubMedGoogle Scholar
  27. 27.
    Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5 acontaining DAA regimens: results of the GS-US-342-1553 study [abstract no. PS024 plus slides]. J Hepatol. 2016;64(2 Suppl 1):S147–8.Google Scholar
  28. 28.
    Asselah T, Shafran S, Bourgeois S, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in HCV infected patients previously treated with placebo: results of the deferred treatment study (GS-US-342-1446 study) [abstract no. SAT-279 plus poster]. J Hepatol. 2016;64(Suppl 2):S827–8.Google Scholar
  29. 29.
    Alqatani S, Zeuzem S, Bourgeois S, et al. On treatment HCV RNA as a predictor of SVR12 in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir fixed dose combination for 12 weeks: an analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies [abstract no. SAT-257 plus poster]. J Hepatol. 2016;64(Suppl 2):S817.CrossRefGoogle Scholar
  30. 30.
    Agarwal K, Patel K, Samuel D, et al. SOF/VEL for 12 weeks results in high SVR12 rates in subjects with negative predictors of response to treatment: an integrated analysis of efficacy from the ASTRAL-1, ASTRAL-2 and ASTRAL-3 studies [abstract no. SAT-195 plus poster]. J Hepatol. 2016;64(Suppl 2):S787–8.CrossRefGoogle Scholar
  31. 31.
    O’Leary J, Brown RS, Reddy KR, et al. Baseline clinical and laboratory parameters associated with clinical benefits of successful HCV treatment with sofosbuvir/velpatasvir in decompensated cirrhotic patients [abstract no. SAT-169 plus slides]. J Hepatol. 2016;64(2 Suppl 1):S774.Google Scholar
  32. 32.
    Younossi ZM, Stepanova M, Charlton M, et al. Efficacy and patient-reported outcomes in decompensated cirrhotic with chronic hepatitis C treated with sofosbuvir and velpatasvir with or without ribavirin: results from ASTRAL-4 clinical trial [abstract no. SAT-285 plus poster]. J Hepatol. 2016;64(Suppl 2):S830.Google Scholar
  33. 33.
    Younossi ZM, Stepanova M, Feld J, et al. Impressive gains in patient-reported outcomes are observed in chronic hepatitis C patients with or without cirrhosis who are treated with sofosbuvir and velpatasvir: results from ASTRAL-1, -2, -3 and-4 [abstract no. FRI-200 plus poster]. J Hepatol. 2016;64(Suppl 2):S628.CrossRefGoogle Scholar
  34. 34.
    Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis. 2016. doi: 10.1093/cid/ciw579.Google Scholar
  35. 35.
    Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65(1):33–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from ASTRAL-2 and -3 clinical trials. Clin Infect Dis. 2016. doi: 10.1093/cid/ciw496.PubMedGoogle Scholar
  37. 37.
    Jacobson I, Brau N, Bourgeois S, et al. The tolerability of SOF/VEL for 12 weeks in >1,000 patients treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies: an integrated safety analysis [abstract no. SAT-168 plus poster]. J Hepatol. 2016;64(Suppl 2):S773–4.CrossRefGoogle Scholar
  38. 38.
    Ward JW, Mermin JH. Simple, effective, but out of reach? Public health implications of HCV drugs. N Engl J Med. 2015;373(27):2678–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations